Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner presents findings from a phase ...

APCCC 2024: Patient Selection for Radioligand Therapy: How to Do It in Clinical Practice and How to Decide on the Number of Cycles. APCCC 2024: Dosing of Radioligand Therapy in Special Situations ...

An external urine collection device (EUCD) is defined as a catheter or product that attaches to the perineum. These collection systems drain urine via tubing attached to a bag or via tubing that ...

IBCN 2024: Quantifying Intra-tumoral Molecular Subtype Heterogeneity in MIBC from Histological Slides using a deep learning approach in the VESPER Trial IBCN 2024: Oncolytic Virotherapy Expressing a ...

The advent of PSMA-based PET imaging has brought a transformative shift in the personalized management of prostate cancer (PCa), with increasing routine clinical utilization across different stages of ...

Dysbiosis may hinder effective tumor immunity and reduce the efficacy of therapies such as immune checkpoint blockade (ICB) in renal cell carcinoma (RCC). CBM588, a product containing live Clostridium ...

Catheters are semi-rigid but flexible tubes. They drain the bladder but block the urethra. The challenge is to produce a catheter that matches as closely as possible to the normal physiological and ...

The predictive value of prostate spherical volume ratio in lower urinary tract symptoms and clinical progression of benign prostatic hyperplasia: a retrospective cohort study. BPH - Benign Prostatic ...

With over 80,000 projected new diagnoses in 2024, bladder cancer remains a significant public health concern. Given the absence of routine screening protocols, identifying high-risk populations ...

Silke Gillessen Sommer presents the phase III PEACE-3 trial results, which evaluated the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone mCRPC. The ...

New Drug Application Initiated with U.S. FDA for TAR-200, the First and Only Intravesical Drug Releasing System for Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer January ...

Renal medullary carcinoma (RMC) is a highly aggressive malignancy defined by the loss of the SMARCB1 tumor suppressor. It mainly affects young individuals of African descent with sickle cell trait, ...